Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

• Main Authors: Damai Santosa (Author), Catharina Suharti (Author), Ignatius Riwanto (Author), Edi Dharmana (Author), Eko Adhi Pangarsa (Author), Budi Setiawan (Author), Suyono Suyono (Author), Mika Lumban Tobing (Author), Suhartono Suhartono (Author), Soeharyo Hadisaputro (Author)
• Formato: Libro
• Publicado: Babol University of Medical Sciences, 2022-02-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background: The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor  (VEGF), tumor necrosis factor-a...